Gossamer Bio, Inc.

NASDAQ:GOSS

Biotechnology

Healthcare
$11.04 +3.24%

+$0.01 today

Market cap
$67.52M
Beta
2.04
P/E (TTM)
-0.2
EPS (TTM)
-$0.77
52W Low $0.11High $3.87

Volume 0.22M

Average 19.76M

GOSS EBITDA Margin

EBITDA as a percentage of revenue.

Gossamer Bio, Inc.NASDAQ: GOSS

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to -257.6%

EBITDA Margin was -257.6% in Q1 FY2026, up 81.7 pp from a year earlier. On a trailing-twelve-month basis it was -304.0%, down 275.3 pp year over year.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 4 analysts of -124.6% for the fiscal year ending Dec 2026, up from -326.9% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-257.6%+63.8 pp QoQ
Last fiscal yearDec 2025
-326.9%-292.1 pp YoY
LTMMar 2026
-304.0%-275.3 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+81.7 pp-1388.0 pp-1469.6 pp
1 year-292.1 pp+202.3 pp+494.4 pp
3 years—+326.9 pp—
5 years+340.8 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-326.9%
Year-over-year change
-292.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How GOSS compares with its peers on the latest reported figures

  • GOSS's LTM Mar 2026 EBITDA Margin of -304.0% is the lowest of the 7 companies compared; the peer median is -115.0%.
  • Its year-over-year change of -275.3 pp is the lowest of 6, against a peer median of +19.9 pp.
GOSS Competitors Peer median
EBITDA Margin for GOSS and competitors
Company Period LTM level YoY 3-year change
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202643.8% +19.9 pp+89.5 pp
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026-25.0% +470.9 pp+71883.1 pp
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025-101.1% ——
PRTAProthena Corporation plcLTM Mar 2026-129.0% -45.6 pp-1804.0 pp
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-185.2% +738962.6 pp+3203.1 pp
RGNXREGENXBIO Inc.LTM Mar 2026-261.2% -183.0 pp+138.5 pp
GOSSGossamer Bio, Inc.LTM Mar 2026-304.0% -275.3 pp—
CRVSCorvus Pharmaceuticals, Inc.FY2025— ——
OLMAOlema Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding GOSS) -115.0%+19.9 pp+138.5 pp

Competitors are the stored peer set for GOSS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000114.7M48.47M
Cost of Revenue00001M
Gross Profit000114.7M47.47M
Gross Margin———100.0%97.9%
Research & Development170.27M170.92M135.3M138.49M174.09M
Selling, General & Admin45.78M47.61M38.46M36.13M37.63M
Operating Expenses216.12M218.59M183.76M174.62M210.72M
Depreciation & Amortization5.17M4.43M4.39M4.15M1M
EBITDA(209.4M)(211.07M)(161.92M)(39.97M)(158.47M)
EBITDA Margin———-34.8%-326.9%
Operating Income(216.12M)(218.59M)(183.76M)(59.92M)(163.25M)
Operating Margin———-52.2%-336.8%
Interest Income761K1.58M2M1.78M1.97M
Interest Expense19.44M13.88M13.51M11.52M10.99M
Other Income / Expenses(17.88M)(10.79M)3.94M4.28M(7.21M)
Income Before Tax(234M)(229.38M)(179.82M)(55.64M)(170.46M)
Pre-Tax Margin———-48.5%-351.7%
Income Tax Expense000893K(88K)
Net Income(234M)(229.38M)(179.82M)(56.53M)(170.37M)
Net Margin———-49.3%-351.5%
EPS (Basic)(3.33)(2.84)(0.80)(0.25)(0.75)
EPS (Diluted)(3.33)(2.84)(1.18)(0.25)(0.75)
Weighted Avg Shares74.84M84.57M225.57M226.23M228.52M
Weighted Avg Shares (Diluted)74.84M84.57M225.57M226.23M228.52M

Gossamer Bio, Inc.

NASDAQ:GOSS

Intrinsic Alpha fair value

Locked

Current Price

$11.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.